Form 8-K - Current report:
SEC Accession No. 0001213900-24-094155
Filing Date
2024-11-04
Accepted
2024-11-04 16:41:11
Documents
17
Period of Report
2024-11-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0219768-8k_cadrenal.htm   iXBRL 8-K 47056
2 FORM OF NEW WARRANT ea021976801ex4-1_cadrenal.htm EX-4.1 110515
3 FORM OF PLACEMENT AGENT WARRANT ea021976801ex4-2_cadrenal.htm EX-4.2 124391
4 FORM OF WARRANT INDUCEMENT AGREEMENT ea021976801ex10-1_cadrenal.htm EX-10.1 55789
5 PRESS RELEASE ISSUED BY CADRENAL THERAPEUTICS, INC., DATED NOVEMBER 1, 2024 (PRI ea021976801ex99-1_cadrenal.htm EX-99.1 10915
  Complete submission text file 0001213900-24-094155.txt   608120

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cvkd-20241101.xsd EX-101.SCH 3015
7 XBRL LABEL FILE cvkd-20241101_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE cvkd-20241101_pre.xml EX-101.PRE 22359
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0219768-8k_cadrenal_htm.xml XML 3799
Mailing Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

EIN.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41596 | Film No.: 241424270
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)